Brief: United Therapeutics Acquires Thymmune Therapeutics
02/07/2026 11:35
BRIEF-United Therapeutics Acquires Thymmune Therapeutics July 2 (Reuters) - United Therapeutics Corp UTHR.O:
ACQUIRES THYMMUNE THERAPEUTICS
DEAL VALUED AT $140 MILLION CASH PLUS UP TO $160 MILLION IN EARN-OUTS BY 2031
Source text: ID:nBw1FZFJja
Further company coverage: UTHR.O
((Reutersbriefs@thomsonreuters.com;))
Recent news on United Therapeutics
See all newsBrief: United Therapeutics Corporation Announces Additional $2 Billion Share Repurchase Authorization
Brief: United Therapeutics Announces FDA Clearance To Proceed With Summit Clinical Trial For Treprostinil Smi In Ph-Copd
Liquidia surges as United Therapeutics settlement removes key litigation risk (updated)
Brief: United Therapeutics Enters Settlement Agreement With Liquidia To Resolve Litigation - SEC Filing
Liquidia surges after $381 million settlement with United Therapeutics for lung disease drug